Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,079 | 131 | 941 |
| Samples | 336 | 57 | 276 |
| Peptides | 245 | 38 | 221 |
Function
CFI · Complement factor I
This gene encodes a serine proteinase that is essential for regulating the complement cascade. The encoded preproprotein is cleaved to produce both heavy and light chains, which are linked by disulfide bonds to form a heterodimeric glycoprotein. This heterodimer can cleave and inactivate the complement components C4b and C3b, and it prevents the assembly of the C3 and C5 convertase enzymes. Defects in this gene cause complement factor I deficiency, an autosomal recessive disease associated with a susceptibility to pyogenic infections. Mutations in this gene have been associated with a predisposition to atypical hemolytic uremic syndrome, a disease characterized by acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Primary glomerulonephritis with immune deposits and age-related macular degeneration are other conditions associated with mutations of this gene. [provided by RefSeq, Dec 2015].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 222 amino-acid changes on canonical ENST00000394634 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CFI · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CFI – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Acute Myeloid Leukemia | 5/90 6% | 0/0 0% |
| Melanoma | 15/210 7% | 73/1899 4% |
| Endometrial Carcinoma | 3/42 7% | 15/612 2% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Cervical Carcinoma | 0/35 0% | 9/422 2% |
| Pancreatic Carcinoma | 0/89 0% | 29/1611 2% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 9/810 1% |
| Colorectal Carcinoma | 13/143 9% | 32/3239 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Gastric Carcinoma | 1/74 1% | 15/1809 1% |
| Other Solid Cancers | 1/94 1% | 12/1515 1% |
| Bladder Carcinoma | 0/58 0% | 7/956 1% |
| Glioma | 0/52 0% | 15/2127 1% |
| Medulloblastoma | 0/0 0% | 3/450 1% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 8/1390 1% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Hepatocellular Carcinoma | 2/46 4% | 9/2210 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Neuroblastoma | 2/87 2% | 2/1331 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 5/2534 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 2/2550 0% |
Mutation Distribution
Where CFI is mutated · all tissues, split by cell line vs tissue
How many mutations in CFI were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,079 mutations in CFI
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|